AMCP 2024: Behind the research with Jacob LaRue and Timothy O’Shea

Ahead of their session, Jacob and Timothy share how Prime/MRx is working alongside providers like Horizon Blue Cross Blue Shield of New Jersey to manage drug waste and rein in spend for specialty drugs without therapeutic impact to patients

April 16, 2024

It’s day one of the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting 2024 in New Orleans, and the energy inside the Ernest N. Morial Convention Center is high as leaders from across the health care space — including Prime Therapeutics/MagellanRx Management (Prime/MRx) — tackle some of the most pressing issues facing the industry.

A key factor driving health care spend today is high-cost specialty drugs, which are often used to treat severe diseases and conditions. That was the focus of the day-one session, “You Can Round That! Establishing and Managing Mandatory Drug Wastage Programs,” featuring Jacob LaRue, assistant vice president of specialty clinical solutions at Prime/MRx, and Timothy O’Shea, manager of clinical pharmacy at Horizon Blue Cross Blue Shield of New Jersey.

We caught up with Jacob and Timothy earlier today to hear how Prime/MRx is working alongside providers, like Horizon Blue Cross Blue Shield of New Jersey, to manage drug waste and rein in spend for specialty drugs without therapeutic impact to patients.

Stay tuned for additional coverage from AMCP Annual 2024 on our newsroom, and follow us on LinkedIn or X (formerly Twitter).

Related news

Perspectives

May 15, 2024

High-Cost Therapy Profile

Detailed information about Fidanacogene elaparvovec-dzkt Intravenous (IV)

Perspectives

May 15, 2024

June 2024 decisions expected from the FDA

Your monthly synopsis of new drugs expected to hit the market

Perspectives

May 15, 2024

Oncology Insights: First-in-class bladder cancer therapy and the Bacillus Calmette-Guérin (BCG) shortage

Approximately 83,000 new bladder cancer cases are diagnosed in the U.S. in each year. Here’s a look at the recent advancements and treatment options for bladder cancer, as well as an update on the BCG shortage.